Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bisoprolol + hydrochlorothiazide** is an oral fixed-dose antihypertensive combination used to treat hypertension. Bisoprolol is a selective beta-1 adrenergic receptor blocker that lowers heart rate, myocardial contractility, and renin release, while hydrochlorothiazide is a thiazide diuretic that inhibits renal sodium and chloride reabsorption, increasing urinary sodium and water excretion. The complementary mechanisms provide additive blood-pressure reduction and are supplied as once-daily film-coated tablets under brands including Ziac, Lodoz, and Concor plus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bisoprolol + hydrochlorothiazide.